biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > XB3 and its cost in the health care system?

<< Previous

Bullboard Posts

Next >>

Post by narmacon Apr 23, 2022 11:26am

246 Views

Post# 34626185

XB3 and its cost in the health care system?

Something I always planned on asking DrDR and have missed doing so,,,,is,,,Just what kind of costs are or will be asscitated with this technology?,,,,is there a reluctance from BP to get in waist deep because of the anticipated cost to produce the conjulates and or other. Is there an expected number or a target number if success is met and what might it look like. How much is reasonable in saving a life is an important discussion for all. It has always been in the back of my mind we will most likely be on the high end of the pricing scale in delivering our compounds to patients. Just thinking here.

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?